NCT01693718View on ClinicalTrials.gov

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2004

Conditions

Head and Neck

Interventions

DRUG

Hydroxyurea

Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.

DRUG

5- Fluorouracil

"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."

DRUG

Cisplatin

Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output \> 100 cc/ hour.

Trial Locations (1)

60653

The University of Chicago, Chicago

All Listed Sponsors

lead

University of Chicago

OTHER

NCT01693718 - A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer | Biotech Hunter | Biotech Hunter